STAINES-UPON-THAMES, United Kingdom, Feb. 23, 2018 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application…Original Article
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
